Anemia of cancer before any treatment;Les anémies des cancéreux avant traitement

Bulletin du Cancer

Volumn 90, Issue 4 SPEC. ISS., 2003, Pages

  Auclerc, Gérard ^a   Meric, Jean Baptiste ^a   Pommeyrol, Arlette ^b   Rixe, Olivier ^a   Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Centre de Charlebourg   (France)

Author keywords

Anemia; Cancer; Physiopathology; Prognosis

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CYTOKINE PRODUCTION; HEMATOPOIESIS; HUMAN; HYPOXIA; PROGNOSIS; QUALITY OF LIFE; REVIEW; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ANEMIA, APLASTIC; CELL HYPOXIA; ERYTHROPOIETIN; FATIGUE; FEMALE; HUMANS; NEOPLASMS; OXYGEN CONSUMPTION; QUALITY OF LIFE; UTERINE CERVICAL NEOPLASMS;

EID: 0037495944     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Pecorellis S. Suboptimal hemoglobin levels: do they impact patients and their therapy? Sem Oncol 2000; 27 (suppl. 4): 1-3.
2. Grau C, Overgaard J. Significance of hemoglobin concentration for treatment outcome. In: Molls M, Vaugel P. eds. Medical radiology: Diagnostic imaging and radiation oncology. Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology. Berlin, German, Springer, 1998: 101-12.
3. Johnson R, Roodman G. Hematologic manifestation of malignancy. Disease-a-Month 1990; 35: 716-68.
4. Lee G. The anemia of chronic disease. Semin Hematol 1983; 20: 61-80.
5. Johnson R, Roodman G. Hematologic manifestations of malignancy. Disease-a-Month 1990; 35: 716-68.
6. Itri LM. Optimal hemoglobin levels for cancer patients. Sem Oncol 2000; 27 (suppl. 4): 12-5.
7. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999; 91: 1616-34.
8. Hefler L, Mayerhofer K, Leibhan B, Obermair A, Reinthaller A, Kainz C, et al. Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol 2000; 21: 309-14.
9. Obermair A, Petru E, Windbichler G, Peters-Engl C, Graf AJ, Stummvoll W, et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep 2000; 7: 639-44.
10. Kumar P. Tumor hypoxia and anemia: impact on the efficacy of radiation therapy. Semin Hematol 2000; 37: 4-8.
11. Lutterbach J, Guttenberger R. Anemia is associated with decrased local control of surgically treated squamous cell carcinomas of the glottic larynx. Int J Radiat Oncol Biol Phys 2000; 48: 1345-50.
12. Henke M, Bechtold C, Momm D. Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues. Int J Radiat Oncol Biol Phys 2000; 48: 339-45.
13. Goldberg MA, Gaut CC, Bunn HF. Erythropoietin mRNA levels are governed by both the rate of gene transcription and post transcriptional events. Blood 1991; 77: 271-5.
14. Stacy DL, Han P. Serum ferritin measervement and the degree of agreement using four techniques. Am J Clin Pathol 1992; 98: 511-5.
15. Hallberg L, Bengtsson C, Lapidus L, Lindstedt G, Lundberg PA, et al. Screening for deficiency: an analysis based on bone-marrow examinations and serum ferritin determination in a population sample of women. Br J Haematol 1993; 85: 787-98.
16. Lee G. The anemia of chronic disease. Semin Hematol 1983; 20: 61-80.
17. Faquin WC, Schnfideer TJ, Goldberg MA. Effects of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992; 79: 1987-94.
18. Fortunel NO, Hatzfeld A, Hatzfeld J. Transforming growth factor-β pleiotropic role in the regulation of hematopiesis. Blood 2000; 96: 2022-36.
19. Miller C, Jones R. Piantadosis Decreased erythropoietin response in patients with anemia of cancer. N Engl J Med 1990; 322: 1689-95.
20. Ludwig H, Fritz E. Anemia in cancer patients. Sem Oncol 1998; 25 (suppl. 7): 2-6.
21. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992; 80: 1639-47.
22. Ulich TR, del Castillo J, Yin S. Tumor necrosis factor exerts dose-dependant effects on erythropoiesis and myelopiesis in vivo. Exp Hematol 1990; 18: 311-6.
23. Means RT, Dessypris EN, Krantz SG. Inhibition of human colony-forming-unit erythroid by tumor necrosis factor requires accessory cells. J Clin Invest 1990; 86: 538-43.
24. Pincus T, Olsen W, Russell DD. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89: 161-8.
25. Abels R, Larholt K, Krantz K, Bryant E. Recombinant human erythropoietin for the treatment of the anemia of cancer. In: Murphy MZ, ed. Blood cell growth factors: their present and future use in hematology and oncology. Dayton OH: Alpha Med 1990: 121-41.
26. Glaspy J, Bukowski R, Steinberg D, Taylor C, Rchekmedyans S, Vadhan-Raj S. Impact of therapy with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-34.
27. Barosi G. Inadequate erythropoietin response to anemia: definition and clinical relavance. Ann Hematol 1994; 68: 215-23.
28. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anemia in patients with solid tumors. Med Oncol 1998; 15 (suppl. 1): 519-28.
29. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998; 25 (suppl. 7): 43-6.
30. Gough, IR, Furnival CM, Schilder L. Assessment of quality of life of patients with advanced cancer. Eur J Cancer Clin Oncol 1983; 19: 1161-5.
31. Demetri GD, Kris M, Wade J. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independant of disease response or tumor type: results from a prospective community oncology study. Procrit study group. J Clin Oncol 1998; 16: 3412-25.
32. 2 during early radiotherapy in cervical cancers: improved local control in primarity hypoxic tumors with «neoxygenation» and the impact of hemoglobin. Int J Radiat Oncol Biol Phys 1999; 45 (suppl. 3): 364-5.
33. 2 tension measurements. Cancer Res 1991; 51: 3316-22.
34. Becker A, Stadler P, Lavey RS, Hansgen G, Kuhnt T, Lautenschlaget C, et al. Severe anemia is associated with poot tumor oxygenation in head and neck squamous cell carcinomas. Int Radia Biol Phys 2000; 42: 459-66.
35. Molls M, Feldmann HJ, Füllet J. Oxygenation of locally advanced recurrent rectal cancer, soft tissue sarcoma and breast cancer. Adv Exp Med Biol 1994; 345: 459-63.
36. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient suply and metabolic microenvitonment of human tumots; a teview. Cancer Res 1989; 49: 6449-65.
37. Green SL, Giaccia AJ. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am 1998; 4: 218-23.
38. Dachs GU, Tozer GM. Hypoxia modulated gene expression: angiogenesis, metastasis and therapeutic exploitation. Eur J Cancer 2000; 36: 1649-60.
39. Reynolds TY, Rockwell S, Glazer PM. Genetic instability induced by the tumor microenvironment. Cancer Res 1996; 56: 5754-7.
40. Graeber TG, Osmania C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996; 379: 88-91.
41. Höckel M, Schlenger K, Aral B. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56: 4509-15.
42. Obermair A, Handisurya A, Kaider A, Sevelda P, Kolbl H, Gitsch G. The relationship of pretreatment serum hemoglobin level to the survival of epithelial ovarian carcinome patients: a prospective review. Cancer 1998; 83: 726-31.
43. Lyng H, Sundfor K, Trope C, Rofstad EK. Disease control of uterine cervical cancer. Clin Cancer Res 2000; 6: 1104-12.
44. Jatzko GR, Lisborg PH, Denk H, Klimpfinger M, Stettner HM. A 10-year experience with Japanese-type radical lymphnode dissection for gastric cancer outside of Japan. Cancer 1995; 76: 1302-12.
45. Werner Wasik M, Schmid CH, Bornstein L, Ball HG, Smith DM, Madocjones H. Prognostic factors for local and distant occurrence in stage I and II cervical carcinoma. Int J Radiat Oncol Biol Phys 1995; 32: 1309-17.
46. Höckel M, Vaupel P. Tumor hypioxia: definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst 2001; 93: 266-76.
47. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953; 26: 638-48.
48. Liang BC. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J Neurooncol 1996; 29: 149-55.
49. Silver DF, Piver MS. Effects of recombinant human erythtopoietin on the antitumor effect of cisplatin in SCID mice bearing human ovatian cancet: a possible oxygen effect. Gynecol Oncol 1999; 73: 280-4.
50. Pedersen D, Sogaard H, Overgaard J, Bentzen SM. Prognostic value of pretreatment factors in patients with locally advanced catcinoma of the uretine cervic treated by radiotherapy alone. Acta Oncol 1995; 34: 787-95.
51. Evans J, Bergst P. The influence of anemia in the results of radiotherapy in carcinoma of the cervix. Radiology 1965; 84: 705-17.
52. Lavey RS, McBride WN. Influence of hematocrit on tumor oxygenation and sensitivity to radiation. Eur J Cancer 1993; 29A (suppl. 6): 5216.
53. 2 measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiather Oncol 1999; 53: 99-104.
54. Fein DA, Lee WR, Hancon AL, Ridge JA, Langer CJ, Curran WJ Jr, et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995; 13: 2077-83.
55. Brizel DM, Dodge RK, Clogh R, Dewhirst MW. Oxygenation of head and neck cancer: charges during radiotherapy and impact on treatment outcome. Radiother Oncol 1999; 53: 113-7.
56. Thews O, Koenig R, Kellher DK. Enhanced radiosensitivity in exprerimental tumours following erythropoietin treatment of chemotherapy-induced anemia. Br J Cancer 1998; 78: 752-6.
57. Henke M, Guttenberger R, Barke A. Erythropoietin for patients undergoing radiotheray: a pilot study. Radiother Oncol 1999; 50: 185-90.
58. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rats tumors. Cancer Res 2001; 61: 1358-61.